Greg Bosch has over 30 years in healthcare leadership of commercial, operations, and R&D global teams. His general management experience in life sciences spans the pharmaceutical, biologics and medical device segments including acquisitions of public and private companies and taking public a company. Greg is currently CEO of Panavance Therapeutics and recently founded Persevere Therapeutics to acquire the Geistlich/Panavance oncology program. Greg was CEO of Geistlich Pharma NA where he led a cross functional team to achieve the market leadership position in regenerative medicine. While at Geistlich, he also led the company's global oncology program developing Panavance's proprietary small molecule drug compound GP-2250 from early R&D through the clinical studies. Earlier in his career he was CEO of PuriCore PLC where he led a successful IPO on the London Stock Exchange. Prior to his experience with PuriCore he held roles of increasing responsibility at Baxter International including GM of the BioSurgery Business. Greg earned his B.A. at Duke University and MBA at DePaul University.